Our IHC results are more consistent with the conclusions of the Xie study [27], who have shown no prognostic value of RRM2 immunoexpression in 117 patients with resectable pancreatic adenocarcinoma. The gene discussed is RRM2; the disease is pancreatic adenocarcinoma.